These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1167 related articles for article (PubMed ID: 26267734)

  • 1. Systemic Treatment of Recalcitrant Pediatric Psoriasis: A Case Series and Literature Review.
    Garber C; Creighton-Smith M; Sorensen EP; Dumont N; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):881-6. PubMed ID: 26267734
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic and Conventional Systemic Therapies Show Similar Safety and Efficacy in Elderly and Adult Patients With Moderate to Severe Psoriasis.
    Garber C; Plotnikova N; Au SC; Sorensen EP; Gottlieb A
    J Drugs Dermatol; 2015 Aug; 14(8):846-52. PubMed ID: 26267729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug safety of systemic treatments for psoriasis: results from The German Psoriasis Registry PsoBest.
    Reich K; Mrowietz U; Radtke MA; Thaci D; Rustenbach SJ; Spehr C; Augustin M
    Arch Dermatol Res; 2015 Dec; 307(10):875-83. PubMed ID: 26358263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic drug survival in Israeli psoriasis patients.
    Shalom G; Cohen AD; Ziv M; Eran CB; Feldhamer I; Freud T; Berman E; Oren S; Hodak E; Pavlovsky L
    J Am Acad Dermatol; 2017 Apr; 76(4):662-669.e1. PubMed ID: 28038888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR.
    Mason KJ; Barker JNWN; Smith CH; Hampton PJ; Lunt M; McElhone K; Warren RB; Yiu ZZN; Griffiths CEM; Burden AD;
    JAMA Dermatol; 2018 May; 154(5):581-588. PubMed ID: 29590279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.
    Phan C; Beauchet A; Burztejn AC; Severino-Freire M; Barbarot S; Girard C; Lasek A; Reguiai Z; Hadj-Rabia S; Abasq C; Brenaut E; Droitcourt C; Perrussel M; Mallet S; Phan A; Lacour JP; Khemis A; Bourrat E; Chaby G; Deborde R; Plantin P; Maruani A; Piram M; Maccari F; Fougerousse AC; Kupfer-Bessaguet I; Balguérie X; Barthelemy H; Martin L; Quiles-Tsimaratos N; Mery-Brossard L; Pallure V; Lons-Danic D; Bouilly-Auvray D; Beylot-Barry M; Puzenat E; Aubin F; Mahé E; ;
    J Eur Acad Dermatol Venereol; 2019 Oct; 33(10):1984-1992. PubMed ID: 30883928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological therapies for psoriasis: Adherence and outcome analysis from a clinical perspective.
    Ross C; Marshman G; Grillo M; Stanford T
    Australas J Dermatol; 2016 May; 57(2):137-40. PubMed ID: 25754697
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 'switcher' patient profile in psoriasis treatment: from traditional to biological and from biological to traditional systemic drugs.
    Tabolli S; Giannantoni P; Paradisi A; Abeni D
    Br J Dermatol; 2015 Jul; 173(1):256-8. PubMed ID: 25422080
    [No Abstract]   [Full Text] [Related]  

  • 9. Tumor Necrosis Factor Inhibitor Primary Failure Predicts Decreased Ustekinumab Efficacy in Psoriasis Patients.
    Sorensen EP; Fanucci KA; Saraiya A; Volf E; Au SC; Argobi Y; Mansfield R; Gottlieb AB
    J Drugs Dermatol; 2015 Aug; 14(8):893-8. PubMed ID: 26267736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries.
    Busard CI; Cohen AD; Wolf P; Gkalpakiotis S; Cazzaniga S; Stern RS; Hutten BA; Feldhamer I; Quehenberger F; Lichem R; Kojanova M; Adenubiova E; Addis A; Naldi L; Spuls PI
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):245-253. PubMed ID: 28898541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Use of Methotrexate, Alone or in Combination With Other Therapies, for the Treatment of Palmoplantar Psoriasis.
    Wald JM; Klufas DM; Strober BE
    J Drugs Dermatol; 2015 Aug; 14(8):888-92. PubMed ID: 26267735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists.
    Mahé E; Beauchet A; Hadj-Rabia S; Mazereeuw-Hautier J; Mallet S; Phan A; Severino-Freire M; Boralevi F; Aubert H; Barthélémy H; Girard C; Martin L; Piram M; Barbarot S; Balguerie X; Zitouni J; Phan C; Di Lernia V;
    Dermatol Ther; 2022 Nov; 35(11):e15828. PubMed ID: 36107157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switching biologics in severe pediatric psoriasis: a retrospective analysis.
    Ramos Pinheiro R; Diamantino F; Cabete J; Brasileiro A; Baptista J; Lopes MJP
    Int J Dermatol; 2017 Dec; 56(12):1461-1464. PubMed ID: 28960270
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation.
    Duarte A; Mebrahtu T; Goncalves PS; Harden M; Murphy R; Palmer S; Woolacott N; Rodgers M; Rothery C
    Health Technol Assess; 2017 Nov; 21(64):1-244. PubMed ID: 29105621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose Modification in Biologic Therapy for Moderate to Severe Psoriasis: A Descriptive Analysis in a Clinical Practice Setting.
    Baniandrés O; Rodríguez-Soria VJ; Romero-Jiménez RM; Suárez R
    Actas Dermosifiliogr; 2015 Sep; 106(7):569-77. PubMed ID: 25935194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic evaluation of systemic therapies for moderate to severe psoriasis.
    Sizto S; Bansback N; Feldman SR; Willian MK; Anis AH
    Br J Dermatol; 2009 Jun; 160(6):1264-72. PubMed ID: 19120346
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of biologics in erythrodermic psoriasis: a multicentre, retrospective study.
    Viguier M; Pagès C; Aubin F; Delaporte E; Descamps V; Lok C; Beylot-Barry M; Séneschal J; Dubertret L; Morand JJ; Dréno B; Bachelez H;
    Br J Dermatol; 2012 Aug; 167(2):417-23. PubMed ID: 22413927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biologic response modifiers and pediatric psoriasis.
    Bellodi Schmidt F; Shah KN
    Pediatr Dermatol; 2015; 32(3):303-20. PubMed ID: 25727936
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug survival of conventional systemic and biologic therapies for moderate-to-severe psoriasis in clinical practice in Spain: prospective results from the SAHARA study.
    Puig L; Carrascosa JM; Daudén E; Sulleiro S; Guisado C
    J Dermatolog Treat; 2020 Jun; 31(4):344-351. PubMed ID: 30888880
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 59.